This article contains content that is written like an advertisement. Please help improve it by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view.(June 2023) (Learn how and when to remove this message)
Halozyme Therapeutics, Inc.
Company type
Public
Traded as
Nasdaq: HALO
S&P 400 component
ISIN
US40637H1095
Industry
Pharmaceuticals
Biotech
Founded
1998; 26 years ago (1998)
Headquarters
San Diego, California, US
Area served
Worldwide
Key people
Helen Torley (president, CEO)
Revenue
US$288 million (2019)[1]
Number of employees
136 (February 17, 2021)
Website
www.halozyme.com
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.[2]
^"Halozyme Therapeutics - Halozyme Reports Fourth Quarter and Full Year 2019 Results". Archived from the original on 2021-01-16. Retrieved 2020-10-10.
^Company Overview of Halozyme Therapeutics, Inc. Bloomberg.com. https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=7931206. Accessed October 20, 2016.
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company...
in a new building in South San Francisco. On June 3, 2015, AbbVie and Halozyme Therapeutics announced that they had entered into a global collaboration...
and Drug Administration (FDA). 3 January 2006. Retrieved 1 May 2020. "Halozyme Therapeutics and Baxter Healthcare Corporation Announce FDA Approval of...
Argenx. 17 December 2021. Retrieved 21 December 2021 – via Business Wire. "Halozyme Announces argenx Receives FDA Approval for Vyvgart Hytrulo With Enhanze...
Genesee Scientific Genomics Institute of the Novartis Research Foundation Halozyme Therapeutics Hologic Illumina Integrated Genetics InvivoGen La Jolla Institute...
Pharmaceuticals, Arvinas, Fate Therapeutics, Agios Pharmaceuticals and Halozyme Therapeutics. Over the decade leading to 2020, it consistently met its...
Global Information
US$288 million (2019)[1]